Telavancin hydrochloride: Glycopeptide antibiotic

Drugs of the Future

Volumn 29, Issue 12, 2004, Pages 1211-1219

  Sorbera, L A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; MOXIFLOXACIN; OXACILLIN; PENICILLIN G; PLACEBO; TEICOPLANIN; TELAVANCIN; UNCLASSIFIED DRUG; VANCOMYCIN; VANCOMYCIN DERIVATIVE;

AGED; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL CELL WALL; BACTERIAL ENDOCARDITIS; CELL MEMBRANE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; FLUSHING; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; TASTE DISORDER; VOMITING;

EID: 13544267650     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.12.865794     Document Type: Article

References (48)

1. Leadbetter, M.R., Linsell, M.S. (Theravance, Inc.). Glycopeptide phosphonate derive. EP 1292612, US 2002022590, US 6635618, WO 0198328.
2. Leadbetter, M.R., Linsell, M., Fatheree, P., Trapp, S., Lam, B., Nodwell, M., Shaw, J., Pace, J., Judice, K. Difunctionalized vancomycin derivative. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27-30, San Diego) 2002, Abst F-367.
3. Schmidt, D. Jr., Sganga, J.D. (Theravance, Inc.). Process for purifying glycopeptide phosphonate derive. US 2003119722, WO 0318608.
4. Leadbetter, M.R., Adams, S.M., Bazzini, B. et al. Hydrophobic vancomycin derivatives with improved ADME properties: Discovery of telavancin (TD-6424). J Antibiot 2004, 57: 326-36.
5. Leadbetter, M., Linsell, M., Lee, J., Liu, J. (Theravance, Inc.). Process for preparing glycopeptide phosphonate derive. US 2003069391, WO 0329270.
6. Neu, H.C. The crisis in antibiotic resistance. Science 1992, 257: 1064-73.
7. Smith, T.L., Pearson, M.L., Wilcox, K.R. et al. Emergence of vancomycin resistance in Staphylococcus aureus. New Engl J Med 1999, 340: 493-501.
8. Sievert, D.M., Boulton, M.L., Stoltman, G. et al. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR 2002, 51: 565-7.
9. Chang, S., Sievert, D.M., Hageman, J.C. et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. New Engl J Med 2003, 348: 1342-7.
10. Rubenstein, E., Prokocimer, P., Talbot, G.H. Safety and tolerability of quinupristin/dalfopristin: Administration guidelines. J Antimicrob Chemother 1999, 44(Suppl. A): 37-46.
11. Gonzales, R.D., Schreckenberger, P.C., Graham, M.B., Kelkar, S., DenBesten, K., Quinn, J.P. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001, 357: 1179.
12. Livermore, D.M. Quinupristin/dalfopristin and linezolid: Where, when, which and whether to use? J Antimicrob Chemother 2000, 46: 347-50.
13. Nagarajan, R. Structure-activity relationships of vancomycin-type glycopeptide antibiotics. J Antibiot 1993, 46: 1181-95.
14. Pavlov, A.Y., Preobrazhenskaya, M.N. Chemical modification of glycopeptide antibiotics [VC1]. Russ J Bioorg Chem 1998, 24: 570-87.
15. Pavlov, A.Y., Lazhko, E.I., Preobrazhenskaya, M.N. A new type of chemical modification of glycopeptides antibiotics: Aminomethylated derivatives of eremomycin and their antibacterial activity. J Antibiot 1997, 50: 509-13.
16. Judice, U.K., Pace, J.L. Semi-synthetic glycopeptide antibacterials. Bioorg Med Chem Lett 2003, 13: 4165-8.
17. Pace, J.L., Krause, K., Johnston, D. et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003, 47: 3602-4.
18. King, A., Phillips, I., Kaniga, K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother 2004, 53: 797-803.
19. Goldstein, E.J., Citron, D.M., Merriam, C.V., Warren, Y.A., Tyrrell, K.L., Fernandez, H.T. In vitro activities of the new semi-synthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic Gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother 2004, 48: 2149-52.
20. Kaniga, K., Blosser, R.S., Karlowsky, J.A., Sahm, D.F. In vitro activity of telavancin (TD-6424) against Bacillus anthracis. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst E-2010.
21. Higgins, D.L., Chand, R., Debabov, D.V. et al. Telavancin bactericidal activity against Staphylococcus aureus is mediated by multiple mechanisms. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, AbSt C1-953.
22. Debabov, D.V., Higgins, D.L., Chang, R. et al. The role of membrane permeabilization in the mode of action of telavancin against vancomycin-sens/tive and -resistant enterococci. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst C1-952.
23. Kaniga, K., Johnston, D., Wu, T., Debabov, D., Krause, K., Pace, J.L., Higgins, D., Christensen, B., Judice, K. Effect of human serum on time-kill curves, minimum inhibitory and bactericidal concentrations of TD-6424 against staphylococci and enterococci. 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14-17, Chicago) 2003, Abst C1-1632.
24. Kaniga, K., Krause, K., Johnston, D., Lane, C., White, L., Wu, T., Debabov, D.V., Pace, J.L., Higgins, D.L. Effect of pH, media and inoculum size on telavancin (TD-6424) in vitro activity. Clin Microbiol Infect 2004, 10(Suppl. 3): Abst P1762.
25. Hegde, S.S., Reyes, N., Wiens, T. et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob Agents Chemother 2004, 48: 3043-50.
26. Hegde, S., Reyes, N., Skinner, R., Kaniga, K. Efficacy of telavancin (TD-6424), a rapidly bactericidal agent with multiple mechanisms of action, in a murine model of MRSA pneumonia. Clin Microbiol Infect 2004, 10(Suppl. 3): Abst P1029.
27. Basuino, L., Madrigal, A.G., Chambers, H.F. Evaluation of TD-6424 in the rabbit model of aortic valve endocarditis (AVE) due to methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-intermediate Staphylococcus aureus (VISA). 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14-17, Chicago) 2003, Abst F-2111.
28. Barriere, S., Shaw, J., Seroogy, J., Kaniga, K., Pace, J., Judice, K., Mant, T. Pharmacokinetic disposition and serum bactericidal activity following IV infusion of single and multiple ascending doses of TD-6424 in healthy male subjects. Clin Microbiol Infect 2003, 9(Suppl. 1): Abst P1214.
29. Barriere, S., Shaw, J.P., Seroogy, J., Spencer, E., Kitt, M. Pharmacokinetics (PK) & safety of a new antibacterial, TD-6424 (TD), in healthy subjects. 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14-17, Chicago) 2003, Abst A-20.
30. Duchin, K., Shaw, J., Spencer, E., Seroogy, J., Barriere, S., Wilbraham, D. Single dose pharmacokinetics (PK) of telavancin (TLV) in healthy elderly subjects. Clin Microbiol Infect 2004, 10(Suppl. 3): Abst P1027.
31. Duchin, K., Shaw, J., Spencer, E., Seroogy, J., Barriere, S., Wilbraham, D. Single dose pharmacokinetics (PK) of telavancin (TLV) in subjects with renal dysfunction. Clin Microbiol Infect 2004, 10(Suppl. 3): Abst P1028.
32. Barriere, S., Genter, F., Spencer, E., Kitt, M., Hoelscher, D., Morganroth, J. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol 2004, 44: 689-95.
33. Stryjewski, M., O'Riordan, W., Lau, W., Pien, F., Fowler, V., Vallee, M., Chu, V., Barriere, S., Kitt, M., Corey, G. Telavancin (TLV) vs standard therapy (ST) for treatment of complicated Gram-positive skin and soft tissue infections (cSSTI). 42nd Annu Meet Infect Dis Soc Am (Sept 30-Oct 3, Boston) 2004, Abst 517.
34. Final phase II results confirm the efficacy of telavancin in cSSSI. DailyDrugNews.com (Daily Essentials) December 13, 2004.
35. Krause, K., Johnston, D., Wu, T., Pace, J., Debabov, D., Judice, K., Higgins, D., Christensen, B., Kaniga, K. Comparative in vitro susceptibility and bactericidal activity of TD-6424 against Streptococcus pneumoniae and non-pneumococcal streptococci from the United States and Europe. 43rdIntersci Conf Antimicrob Agents Chemother (Sept 14-17, Chicago) 2003, Abst C1-1634.
36. Gander, S., Kinnaird, A., Baklavadaki, L., Finch, R. The effect of the novel glycopeptide, TD-6424, on biofilms of susceptible and resistant staphylococci. 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14-17, Chicago) 2003, Abst F-2110.
37. Hegde, S.S., Reyes, N., Wiens, T., Skinner, R., McCullough, J., Vanasse, N., Judice, K. In vivo pharmacodynamics of TD-6424, a novel rapidly bactericidal antibiotic against Gram-positive bacteria. 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14-17, Chicago) 2003, Abst F-2108.
38. Debabov, D.V., Pace, J., Nodwell, M. et al. TD-6424, a novel rapidly bactericidal concentration-dependent antibiotic, acts through a unique dual mode of action. 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14-17, Chicago) 2003, Abst C1-1809.
39. Krause, K., Debabov, D., Pace, J., Kaniga, K. Low frequency of spontaneous resistance to TD-6424 and delayed resistance selection in vitro among staphylococci and enterococci. 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14-17, Chicago) 2003, Abst C1-1810.
40. Wu, T., Pace, J., Farrington, L., Debabov, D., Krause, K., Johnston, D., Judice, K., Higgins, D., Christensen, B., Kaniga, K. Comparative in vitro activity of TD-6424 against clinical isolates of Enterococcus faecalis and Enterococcus faecium. 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14-17, Chicago) 2003, Abst C1-1633.
41. Citron, D.M., Goldstein, E.J.C. In vitro activities of TD-6424, a novel antiinfective with multiple mechanisms of action, vancomycin (V), daptomycin (D), linezolid (L), and four other agents against anaerobic Gram-positive organisms and Corynebacterium spp. 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14-17, Chicago) 2003, Abst C1-1639.
42. Shaw, J., Adams, S., Li, D., Seroogy, J., Jaw-Tsai, S. Pharmacokinetics of TD-6424, a novel rapidly bactericidal concentration-dependent antibiotic, in preclinical species. 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14-17, Chicago) 2003, Abst F-2109.
43. Barriere, S., Genter, F., Spencer, E., Kitt, M., Hoelscher, D., Morganroth, J. A randomized, double-blind, placebo- and positive-controlled study of the effects of a new antibacterial, TD-6424 on cardiac repolarization (the QTc interval) in healthy subjects. Clin Microbiol Infect 2003, 9(Suppl. 1): Abst O144.
44. King, A., Phillips, I., Farrington, L., Pace, J., Kaniga, K. Comparative in vitro activity of TD-6424, a rapidly bactericidal, concentration-dependent antibiotic with multiple mechanisms of action against Gram-positive bacteria. Clin Microbiol Infect 2003, 9(Suppl. 1): Abst P799.
45. Tenover, F.C., Weigel, L.M., Appelbaum, P.C. et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 2004, 48: 275-80.
46. Cottagnoud, P., Cottagnoud, M., Acosta, F., Kühn, F., Pfister, M., Platz, L., Stucki, A. Telavancin (TLV) is highly efficacious against a penicillin-resistant pneumococcal strain in the rabbit meningitis model. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst B-938.
47. Leuthner, K.D., Cheung, C., Rybak, M.J. Comparison of telavancin versus daptomycin, linezolid and quinupristin/dalfopristin against 49 glycopeptide non-susceptible Staphylococcus species (GISS) including hetero-resistant (hGISS) and vancomycin resistant S.aureus (VRSA). 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst E-2007.
48. Eliopoulos, G.M., Wennersten, C.B., Sakoulas, G., Moellering, R.C. Jr. In vitro bactericidal activity of telavancin (TLV) against S. aureus with relative tolerance to vancomycin (VAN). 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst E-2011.